Generic Co. Loses Another Round At PTAB In Zomig IP Fight
The Patent Trial and Appeal Board on Tuesday rejected a petition by generic-drug maker Lannett Holdings seeking review of claims of AstraZeneca's patent covering Zomig nasal spray because the bid was...To view the full article, register now.
Already a subscriber? Click here to view full article